Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Medical Dermatology Potpourri: Challenges Faced and Lessons Learned
Description
The presentation focused on the complexities of medical dermatology, particularly discussing a case of a 52-year-old woman who developed Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) after starting leflunomide. The session emphasized the importance of understanding the nuances of drug-induced skin eruptions and highlighted significant findings from recent literature on DRESS, including its classification, management, and incidence rates among diverse populations, particularly focusing on variations in presentation among people of color. Key diagnostic criteria and processes were outlined, which involve a thorough evaluation of the patient's drug history and the necessity of managing potential complications from DRESS, such as organ failure. The discussion introduced new steroid-sparing therapies, including cyclosporine and dupilumab, and highlighted the need for ongoing evaluation and individualized treatment plans. Furthermore, the presentation acknowledged advancements in precision medicine, which could help enhance treatment efficacy in similar future cases. The speaker concluded by stressing the importance of continued research in dermatological conditions like DRESS and the nurturing role of healthcare providers in alleviating patient anxieties regarding drug sensitivities, echoing a broader call for improved awareness and management strategies in the dermatology field.
View moreConclusions
- DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) diagnosis is complex and requires comprehensive evaluation including possible skin biopsy.
- The incidence of DRESS ranges from 1 in 1,000 to 1 in 10,000 depending on the drug involved.
- Common drug culprits associated with DRESS include anticonvulsants, antibiotics, and allopurinol.
- DRESS has a latency period of two to six weeks after drug exposure, and it can evolve over 90 days in some patients.
- There is a range of systemic manifestations of DRESS including hepatic, renal, pulmonary, and cardiac complications.
- The mortality rate associated with DRESS has decreased to 1-6%, with hepatic necrosis being the most common cause of death.
- Relapse of DRESS can occur even after drug withdrawal, indicating the need for caution in medication prescribing.
- Special considerations in the management of DRESS are necessary for persons of color, who may have different clinical presentations and complications.
- Severe DRESS should be classified to guide treatment, with options including systemic corticosteroids and steroid-sparing therapies.
- Recent studies have shown potential benefits of IL-5 inhibitors and dupilumab in managing DRESS and reducing corticosteroid use.
- Kardaun SH et al. Br J Dermatol 2007;156:609-11.
- Kardaun SH et al. Br J Dermatol 2013;169:1071-80.
- Litt JZ and Shear NH. Litt's Drug Eruption and Reaction Database. Boca Raton, FL: CRC Press; 2022.
- Emge DP et al. Abstract of the 2022 Medical Dermatology Society Annual Meeting. Boston, MA.
- Tetart F et al. JAMA Dermatol 2014;150:206-7.
- Bluestein SB et al. J Allergy Clin Immunol Pract 2021;9:3208-11 e1.
- Abecassis S et al. J Am Acad Dermatol 2004;51:827-30.
- Chen YC et al. J Am Acad Dermatol 2013;68:459-65.
- Mizukawa Y et al. J Invest Dermatol 2022;142:960-8.e9.
- Bassir F et al. J Allergy Clin Immunol Pract. 2023 Aug 10:S2213-2198(23)00908-X.
- Bean EL et al. Dermatol Online J. 2023;29(1).
- Jörg L et al. Clin Transl Allergy 2020;10:52.
- Nguyen E et al. JAMA Dermatol 2020;156:704-6.
- Damsky WE et al. JAAD Case Rep 2019;5:1018-26.
- Dubin DP et al. J Allergy Clin Immunol Pract. 2023:S2213-2198(23)00950-9.
- Shen CH, et al. J Investig Allergol Clin Immunol. 2023 Oct 4:0. doi: 10.18176/jiaci.0944.
- Joly P et al. Arch Dermatol 2012;148:543-4.
- Sim DW et al. Clin Transl Sci 2022;15:782-8.
- Schmid-Grendelmeier et al. J Allergy Clin Immunol Pract 2021:9:481-483.e2.
- Gschwend A et al. Allergo J Int 2022:1-8.